OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in AI-enabled antibody discovery platforms, having completed its business combination with Avista Public Acquisition Corp. II — sponsored by Avista Capital Partners — in late 2022. The company provides its proprietary antibody discovery technologies to pharmaceutical and biotechnology partners seeking to develop novel therapeutics. OmniAb has remained an active public reporting company since its de-SPAC transaction, filing an 8-K with the SEC on June 18, 2026. For full filing history, sponsor profiles, and SPAC transaction analytics covering OmniAb and hundreds of other de-SPAC companies, sign up for complete data access at SpacDesk.